Ascendis Pharma A/S (NASDAQ:ASND) Expected to Post Quarterly Sales of $2.26 Million

Equities analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will post $2.26 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Ascendis Pharma A/S’s earnings. The lowest sales estimate is $1.52 million and the highest is $2.77 million. Ascendis Pharma A/S reported sales of $12.00 million in the same quarter last year, which indicates a negative year over year growth rate of 81.2%. The company is scheduled to report its next quarterly earnings report on Wednesday, April 1st.

On average, analysts expect that Ascendis Pharma A/S will report full-year sales of $14.00 million for the current year, with estimates ranging from $12.08 million to $15.07 million. For the next year, analysts forecast that the firm will post sales of $6.93 million, with estimates ranging from $1.12 million to $15.29 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Monday, November 18th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.37) by $0.78. The firm had revenue of $2.49 million during the quarter, compared to analysts’ expectations of $1.88 million. Ascendis Pharma A/S had a negative net margin of 789.80% and a negative return on equity of 29.04%.

Several research analysts have recently weighed in on ASND shares. Leerink Swann reiterated an “outperform” rating and issued a $152.00 price target (up previously from $140.00) on shares of Ascendis Pharma A/S in a report on Tuesday, December 3rd. ValuEngine cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Morgan Stanley upped their price target on shares of Ascendis Pharma A/S from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Friday. Wedbush reiterated a “buy” rating and issued a $186.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, November 19th. Finally, Zacks Investment Research cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $153.00.

NASDAQ ASND traded down $1.34 during trading on Monday, reaching $139.13. 216,784 shares of the stock traded hands, compared to its average volume of 215,328. The firm has a market cap of $5.92 billion, a price-to-earnings ratio of -32.58 and a beta of 0.67. Ascendis Pharma A/S has a fifty-two week low of $66.11 and a fifty-two week high of $142.94. The company has a quick ratio of 15.75, a current ratio of 15.74 and a debt-to-equity ratio of 0.05. The stock’s 50-day moving average price is $126.71 and its 200 day moving average price is $113.70.

Several institutional investors have recently added to or reduced their stakes in the company. Lindbrook Capital LLC lifted its position in shares of Ascendis Pharma A/S by 83.2% in the third quarter. Lindbrook Capital LLC now owns 852 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 387 shares in the last quarter. LPL Financial LLC lifted its position in shares of Ascendis Pharma A/S by 6.2% in the second quarter. LPL Financial LLC now owns 2,233 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 131 shares in the last quarter. JGP Global Gestao de Recursos Ltda. lifted its position in shares of Ascendis Pharma A/S by 12.7% in the third quarter. JGP Global Gestao de Recursos Ltda. now owns 3,360 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 379 shares in the last quarter. Meadow Creek Investment Management LLC lifted its position in shares of Ascendis Pharma A/S by 6.7% in the second quarter. Meadow Creek Investment Management LLC now owns 3,168 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 198 shares in the last quarter. Finally, Stifel Financial Corp lifted its position in shares of Ascendis Pharma A/S by 62.5% in the third quarter. Stifel Financial Corp now owns 4,203 shares of the biotechnology company’s stock worth $407,000 after purchasing an additional 1,616 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: Quantitative Easing

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.